参考文献/References:
1 白耀. 甲状腺病学-基础与临床.北京:科学技术文献出版社,2003.244-636.
2 张承刚. 主编.甲状腺疾病核素治疗学.北京:原子能出版社,2003.166-349.
3 Bolanos F,Gonzalez-Ortiz M,Duron H,et al. Remission of Graves’ hyperthyroidism treated with methimazole.Rev Invest Clin,2002,54(4):307-310.
4 Menendez E,Anda E,Barberia JJ,et al. Recurrence and prognostic factors after treatment with antithyroid agents in Graves-Basedow disease.Multicenter study in Northern Spain.Rev Clin Esp,2000,200(2):69-73.
5 Quadbeck B,Hoermann R,Roggenbuck U,et al. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves’ disease.Thyroid,2005,15(9):1047-1054.
6 Cooper DS. Hyperthyroidism.Lancet,2003,362(9382):459-468.
7 Cooper DS. Antithyroid Drugs.N Engl J Med,2005,352(9):905-917.
8 Woeber KA. Methimazole-induced hepatotoxicity.Endocr Pract,2002,8(3):222-224.
9 高莹,赵明辉,叶华,等. 19例丙基硫氧嘧啶引起抗中性粒细胞胞浆抗体相关小血管炎的临床分析.中华内分泌代谢杂志,2006,22(2):124-126.
10 Gao Y,Zhao MH,Guo XH,et al. The prevalence and target antigens of antithyroid drugs induced antineutrophil cytoplasmic antibodies(ANCA) in Chinese patients with hyperthyroidism.Endocr Res,2004,(3002):205-213.
11 Guma M,Salinas I,Reverter JL,et al. Frequency of antineutrophil cytoplasmic antibody in Graves’ disease patients treated with methimazole.J Clin Endocrionl Metab,2003,88(5):2141-2146.
12 Streetman DD,Khanderia U. Diagnosis and treatment of Graves disease.Ann Pharmacother,2003,37(7-8):1100-1109.
13 Ginsberg J. Diagnosis and management of Graves’ disease.CMAJ,2003,168(5):575-585.
14 Giovanella L,De Palma D,Ceriani L,et al. Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach.Clinical results. Radiol Med(Torino),2000,100(6):480-483.
15 Metso S,Jaatinen P,Huhtala H,et al. Long-term follow-up study of radioiodine treatment of hyperthyroidism.Clin Endocrinol(Oxf),2004,61(5):641-648.
16 Santos RB,Romaldini JH,Ward LS. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves’ disease.Thyroid,2004,14(7):525-530.
17 康增寿,戴维信,杜永昌. 131I治疗儿童Graves’甲亢安全、有效.国外医学·放射医学核医学分册,2001,25(4):149-152.
18 Stocker DJ,Foster SS,Solomon BL,et al. Thyroid cancer yield in patients with Graves’ disease selected for surgery on the basis of cold scintiscan defects.Thyroid,2002,12(4):305-311.
19 Franklyn JA. The management of hyperthyroidism.N Engl J Med,1994,330(24):1731-1738.
20 邢家骝.主编.131碘治疗甲状腺疾病.北京:人民卫生出版社,2002.265-267.
21 Gittoes NJ,Franklyn JA. Current treatment guidelines.Drugs,1998,55(4):543-553.
22 Abraham P,Avenell A,Park GM,et al. A systematic review of drug therapy for Graves’ hyperthyroidism.Eur J Endocrinol,2005,153(4):489-498.
23 Andrade VA,Gross JL,Maia AL. Radioactive iodine therapy in Graves’ hyperthyroidism.Arq Bras Endocrinol Metabol,2004,48(1):159-165.
24 Reiners C. Radioiodine therapy for Graves’ disease:problems and new developments.Z Arztl Fortbild Qualitatssich,2004,98(suppl 5):55-62.
25 Azizi F,Ataie L,Hedayati M,et al. Effect of long-term continuous methimazole treatment of hyperthyroidism:comparison with radioiodine.Eur J Endocrinol,2005,152(5):695-701.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[3]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[4]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[5]杨宝军.131I治疗甲亢合并特发性血小板减少性紫癜一例[J].国际放射医学核医学杂志,2015,39(6):511.[doi:10.3760/cma.j.issn.1673-4114.2015.06.017]
[6]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[7]张瑞国,秦岚,张又萍,等.初诊Graves甲亢合并肝损害及其影响因素的临床分析[J].国际放射医学核医学杂志,2013,37(5):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
ZHANG Rui-guo,QIN Lan,ZHANG You-ping,et al.Clinical study of hepatic dysfunction and its correlative factors in newly diagnosed patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
[8]黄春玲,查金顺,蒋婷吟.甲状腺功能亢进症患者血浆中TNF-α1和IL-2水平的临床分析[J].国际放射医学核医学杂志,2012,36(2):92.[doi:10.3760/cma.j.issn.1673-4114.2012.02.008]
HUANG Chunling,ZHA Jin-shun,JIANG Ting-yin.The clinical analysis of the TNF-α1 and IL-2 levels in patients with hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(4):92.[doi:10.3760/cma.j.issn.1673-4114.2012.02.008]
[9]孟召伟,谭建.解读美国甲状腺协会和临床内分泌医师协会2011年甲亢诊治指南[J].国际放射医学核医学杂志,2011,35(4):193.[doi:10.3760/cma.j.issn.1673-4114.2011.04.001]
MENG Zhao-wei,TAN Jian.Reading and analysis on management guidelines for hyperthyroidism published in 2011 by American Thyroid Association and American Association of Clinical Endocrinologists[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(4):193.[doi:10.3760/cma.j.issn.1673-4114.2011.04.001]
[10]王春梅,王雪梅.131I治疗甲亢的现状和研究进展[J].国际放射医学核医学杂志,2010,34(1):31.[doi:10.3760/cma.j.issn.1673-4114.2010.01.008]
WANG Chun-mei,WANG Xue-mei.The development and current status of 131I treatment for hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(4):31.[doi:10.3760/cma.j.issn.1673-4114.2010.01.008]